Bi/multispecific drugs in oncology present key opportunities: precision targeting, innovative immune modulation, and personalized therapies. With rapid pipeline growth, breakthrough approvals, and ...
TAGMO Clinical Readouts -- Initial results for head and neck, and upper GI adenocarcinoma cohorts are expected midyear, with ...
Detailed price information for Zai Lab Ltd ADR (ZLAB-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results